- Trials with a EudraCT protocol (28)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
28 result(s) found for: Endotoxin.
Displaying page 1 of 2.
| EudraCT Number: 2018-004285-34 | Sponsor Protocol Number: STH20370 | Start Date*: 2019-01-18 | |||||||||||
| Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust | |||||||||||||
| Full Title: The impact of aspirin dose modification on the innate immune response - WILL lOWer dose aspirin Therapy ReducE the response to Endotoxin? – (WILLOW TREE) | |||||||||||||
| Medical condition: Acute coronary syndrome | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2010-023681-45 | Sponsor Protocol Number: EndotoxinexpoIII | Start Date*: 2012-05-04 |
| Sponsor Name:Verksamhetsområde Geriatrik, Lungmedicin och Allergologi vid Sahlgrenska Universitetssjukhuset | ||
| Full Title: Endotoxin-induced immune response in the lower respiratory tract in smokers with and without chronic bronchitis (CB) and / or chronic obstructive pulmonary disease (COPD) | ||
| Medical condition: Airway inflammation in smokers with and without COPD and / or CB | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: SE (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2016-001971-61 | Sponsor Protocol Number: SALYCENDO | Start Date*: 2016-08-29 |
| Sponsor Name:Radboudumc | ||
| Full Title: The effects of acetylsalicylic acid on immunoparalysis following human endotoxemia. | ||
| Medical condition: We will investigate the effects of acetylsalicylic acid on immunoparalysis following human endotoxemia in healthy male volunteers | ||
| Disease: | ||
| Population Age: Adults | Gender: Male | |
| Trial protocol: NL (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2015-004023-31 | Sponsor Protocol Number: LPS-Fluenz | Start Date*: 2016-01-06 |
| Sponsor Name:Radboudumc | ||
| Full Title: The effects of endotoxin challenge on the immune response elicited by a subsequent challenge with Fluenz™ in healthy volunteers, a pilot study | ||
| Medical condition: Inflammatory conditions in general and immunosuppressive conditions is particular | ||
| Disease: | ||
| Population Age: Adults | Gender: Male | |
| Trial protocol: NL (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2010-020204-30 | Sponsor Protocol Number: E5564-G000-103 | Start Date*: Information not available in EudraCT |
| Sponsor Name:Eisai Limited [...] | ||
| Full Title: A Multicenter, Open-label, Sequential, Multiple-dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Efficacy or Eritoran in Descending Age Groups of Pediatric S... | ||
| Medical condition: Severe Sepsis | ||
| Disease: | ||
| Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: GB (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2005-003041-14 | Sponsor Protocol Number: 565 | Start Date*: 2005-09-20 |
| Sponsor Name:Department of Clinical Pharmacology, Medical University of Vienna | ||
| Full Title: Anti-inflammatory effect of statins in the human endotoxin model | ||
| Medical condition: Healthy volunteers are tested in an endotoxemia model | ||
| Disease: | ||
| Population Age: Adults | Gender: Male | |
| Trial protocol: AT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2013-005520-42 | Sponsor Protocol Number: BCG-LPS | Start Date*: 2014-04-28 | |||||||||||
| Sponsor Name:Radboud University Nijmegen Medical Centre | |||||||||||||
| Full Title: The effects of BCG-vaccination on the innate immune response and immunoparalysis in healthy volunteers | |||||||||||||
| Medical condition: sepsis induced immunoparalysis | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male | ||||||||||||
| Trial protocol: NL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-005687-97 | Sponsor Protocol Number: NoSIRS | Start Date*: 2013-06-20 |
| Sponsor Name:Medtronic Inc. | ||
| Full Title: Effects of Transvenous Vagus Nerve Stimulation on Immune Response: a pilot study | ||
| Medical condition: Possible future indications: inflammatory conditions in general | ||
| Disease: | ||
| Population Age: Adults | Gender: Male | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2012-005514-18 | Sponsor Protocol Number: STH17062 | Start Date*: 2013-02-07 | |||||||||||
| Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust | |||||||||||||
| Full Title: Study of the Effect of Ticagrelor and Clopidogrel on the Immune Response of Healthy Volunteers | |||||||||||||
| Medical condition: Immune response to endotoxin influenced by anti-platelet medications. | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-004202-60 | Sponsor Protocol Number: CER-001-SEP_AKI_01 | Start Date*: 2021-01-13 | |||||||||||
| Sponsor Name:CERENIS THERAPEUTICS | |||||||||||||
| Full Title: A RAndomized pilot study comparing short-term CER-001 infusions at different doses to prevent Sepsis-induced acute kidney injury | |||||||||||||
| Medical condition: Sepsis due to intra-abdominal cavity infection or urosepsis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2007-003769-41 | Sponsor Protocol Number: ALB1 | Start Date*: 2008-01-31 | |||||||||||
| Sponsor Name:Medical University Graz | |||||||||||||
| Full Title: Albumin in acute-on-chronic liver failure: More than just volume? A randomized, controlled study | |||||||||||||
| Medical condition: Spntaneous bacterial peritonitis | |||||||||||||
|
|||||||||||||
| Population Age: | Gender: Male, Female | ||||||||||||
| Trial protocol: AT (Completed) | |||||||||||||
| Trial results: Removed from public view | |||||||||||||
| EudraCT Number: 2006-001774-24 | Sponsor Protocol Number: 3574 | Start Date*: 2006-09-13 |
| Sponsor Name:Newcastle u Tyne Hospitals NHS Trust | ||
| Full Title: INTESTINAL MICRO-ORGANISMS IN THE PATHOGENESIS OF NASH AND THE ROLE OF MODULATION OF ENTERIC BACTERIA IN TREATMENT. | ||
| Medical condition: Non alcoholic fatty liver disease (NAFLD)/steatohepatitis (NASH) | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (GB - no longer in EU/EEA) | ||
| Trial results: View results | ||
| EudraCT Number: 2010-024138-43 | Sponsor Protocol Number: AN-2010/28 | Start Date*: 2011-06-27 | |||||||||||
| Sponsor Name:Javier Pascual Ramírez | |||||||||||||
| Full Title: Protocolo de suero salino hipertónico y terlipresina en la mejora funcional del shock séptico | |||||||||||||
| Medical condition: Shock séptico | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-000275-36 | Sponsor Protocol Number: CSUB0202 | Start Date*: 2021-04-23 |
| Sponsor Name:Sahlgrenska University Hospital | ||
| Full Title: Prevention of Glucocorticoid induced impairment of bone metabolism – A Randomized, Placebo-Controlled, Single Centre Clinical Trial | ||
| Medical condition: Oral glucocorticoid (GC) therapy leads to a rapid and profound effects on bone metabolism.The gut microbiota is involved in regulating bone metabolism.Lactobacillus reuteri (LR) has been shown to h... | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: SE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2006-002273-41 | Sponsor Protocol Number: OPHT-110106 | Start Date*: 2006-06-12 |
| Sponsor Name:Medical University of Vienna; Clinical Pharmacology | ||
| Full Title: Effect of antioxidants on ocular blood flow, endothelial function, and cytokine levels in LPS induced inflammatory model in humans. | ||
| Medical condition: only healthy volunteers are involved | ||
| Disease: | ||
| Population Age: Adults | Gender: Male | |
| Trial protocol: AT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2009-010138-22 | Sponsor Protocol Number: OPHT-101108 | Start Date*: 2009-04-02 |
| Sponsor Name:Universitätsklinik für Klinische Pharmakologie | ||
| Full Title: Effect of antioxidants on oxygen induced vasoconstriction in LPS induced inflammatory model in humans | ||
| Medical condition: Healthy volunteers are included | ||
| Disease: | ||
| Population Age: Adults | Gender: Male | |
| Trial protocol: AT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2010-020141-26 | Sponsor Protocol Number: D3320C00001 | Start Date*: 2010-08-30 | |||||||||||
| Sponsor Name:AstraZeneca AB | |||||||||||||
| Full Title: A Single-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Phase IIa Study to Investigate the Effects of 100mg AZD2423 as an oral tablet in Subjects with Mild COPD Following Seg... | |||||||||||||
| Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-000488-34 | Sponsor Protocol Number: PVTRIFA2017 | Start Date*: 2017-06-14 | |||||||||||
| Sponsor Name:UMBERTO I - POLICLINICO DI ROMA | |||||||||||||
| Full Title: RIFAXIMIN BLUNTED HIGHER LEVELS OF ENDOTOXIN IN CIRRHOSIS PATIENTS: A RANDOMIZED, DOUBLE BLIND, SHORT TERM INTERVENTIONAL TRIAL. | |||||||||||||
| Medical condition: PATIENTS WITH CIRRHOSIS CHILD PUGH B or C Classes | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2005-005537-35 | Sponsor Protocol Number: E5564-G000-301 | Start Date*: 2006-08-30 | |||||||||||
| Sponsor Name:Eisai Limited | |||||||||||||
| Full Title: ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients with Severe Sepsis | |||||||||||||
| Medical condition: Severe Sepsis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) NL (Completed) AT (Completed) CZ (Completed) ES (Completed) DE (Completed) PT (Prematurely Ended) IT (Prematurely Ended) GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-002264-33 | Sponsor Protocol Number: AH01 | Start Date*: 2014-08-25 | |||||||||||
| Sponsor Name:Ole Hamberg | |||||||||||||
| Full Title: Rifaximin in alcoholic hepatitis: effects on inflammatory and metabolic markers. | |||||||||||||
| Medical condition: Alcoholic hepatitis. | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.